DRP®: Picking the Right Patients

A patient’s unique “fingerprint” of ~150 mRNA genes predicts responsiveness to a drug

① In a panel of human cancer cell lines, patterns in drug sensitivity reflect mechanism of action of a drug.  Panels of several hundred cell lines from the National Cancer Institute (NCI) and other significant repositories total more than 100,000 drugs.

② Cancer cell line patterns in sensitivity testing data to our drug candidate are correlated with the activity (mRNA) of 20,000 genes in the cancer cell lines. The number of genes vary. Typically 200 mRNAs will form the raw DRP, e.g. 100 mRNAs correlated to sensitivity and 100 mRNAs correlated to resistance.

Refined to clinical relevance. By “filtering” data created from meta analysis of 3,255 human tumor samples, each providing 20,000 data points to eliminate clinically irrelevant gene expressions (e.g. background noise), we typically end up with 150 relevant genes. This is generates the drug-specific DRP®.

④ mRNA data from the individual patient’s tumor is matched to the drug specific DRP®.

 

DRP® is a trademark of  Medical Prognosis Institute A/S.